F. Belgore

发表

Measurement of free and complexed soluble vascular endothelial growth factor receptor, Flt-1, in fluid samples: development and application of two new immunoassays.

G. Lip, A. Blann, F. Belgore, 2001, Clinical science.

Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension.

G. Lip, A. Blann, D. Beevers, 2001, The American journal of cardiology.

Soluble vascular endothelial growth factor, soluble VEGF receptor Flt-1 and endothelial function in healthy smokers.

G. Lip, H. Klein, C. Schmidt-Lucke, 2005, International journal of cardiology.

Localisation of members of the vascular endothelial growth factor (VEGF) family and their receptors in human atherosclerotic arteries

G. Lip, A. Blann, A. Ahmed, 2004, Journal of Clinical Pathology.

Circulating Levels of Vegf-A, VEGF-D and soluble VEGF-A Receptor (sFlt-1) in Human Breast Cancer

F. Hoar, P. Stonelake, F. Belgore, 2004, The International journal of biological markers.

Circulating levels of VEGF-A, VEGF-D and soluble VEGF-A receptor (sFlt-1) in human breast cancer.

G. Lip, F. Hoar, P. Stonelake, 2004, The International journal of biological markers.

Vascular endothelial growth factor and its receptor, Flt-1, in smokers and non-smokers.

G. Lip, A. Blann, F. Belgore, 2000, British journal of biomedical science.

Plasma levels of vascular endothelial growth factor (VEGF) in haematological cancers.

G. Lip, A. Blann, D. Bareford, 2000, British journal of haematology.

Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes.

Gregory Y H Lip, Stanley Silverman, G. Lip, 2002, Clinical science.

Basic fibrobrast growth factor induces the secretion of vascular endothelial growth factor by human aortic smooth muscle cells but not by endothelial cells

A. Blann, F. Belgore, G. Lip, 2003, European journal of clinical investigation.

Angiogenesis in myocardial infarction. An acute or chronic process?

G. Lip, A. Blann, N. Chung, 2002, European heart journal.

Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]).

G. Lip, A. Blann, D. Beevers, 2003, The American journal of cardiology.

Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management.

G. Lip, A. Blann, D. Beevers, 2003, American journal of hypertension.

Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate.

G. Lip, A. Blann, J. Constans, 2001, The American journal of cardiology.

Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease

G. Lip, A. Blann, F. L. Li-Saw-Hee, 2003, Heart.

Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment.

G. Lip, M. Hope-Ross, A. Blann, 2000, Investigative ophthalmology & visual science.

Is the Hypercoagulable State in Atrial Fibrillation Mediated by Vascular Endothelial Growth Factor?

G. Lip, A. Blann, Dwayne S.G. Conway, 2002, Stroke.

Plasma levels of vascular endothelial growth factor (VEGF) and its receptor, flt‐1, in haematological cancers: A comparison with breast cancer

G. Lip, A. Blann, M. Wadley, 2001, American journal of hematology.

sFlt-1, a potential antagonist for exogenous VEGF.

G. Lip, A. Blann, F. Belgore, 2000, Circulation.